Shopping Cart 0
Cart Subtotal
AED 0

Cardiovascular pharmaceuticals Market in India 2014

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 3487

Details

Netscribes' latest market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide

Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well

READ MORE

Table Of Content

Scope

Slide 1: Executive Summary

Macroeconomic Indicators

Slide 2: GDP at Factor Cost: Quarterly (2010-11, 2011-12, 2012-13, 2013-14), Inflation Rate: Monthly (Jun 2013-Nov 2013)

Slide 3: Gross Fiscal Deficit: Monthly (Feb 2013-Jul 2013), Exchange Rate: Half Yearly (Oct 2013-March 2014)

Slide 4: Lending Rate: Annual (2008-09, 2009-10, 2010-11, 2011-12), Trade Balance: Annual (2010-11, 2011-12, 2012-13, 2013-14), FDI: Annual (2009-10, 2010-11, 2011-12, 2012-13)

Introduction

Slide 5: Major Drug Classes

Market Overview

Slide 6-7: Global Cardiovascular Pharmaceutical Market-Overview, Indian Cardiovascular Pharmaceutical Market-Overview, Market Size & Growth (2013-2018e)

Value Chain

Slide 8-9: Market Value Chain Analysis

Drivers & Challenges

Slide 10: Drivers and Challenges-Summary

Slide 11-14: Drivers

Slide 15: Challenges

Government Initiatives

Slide 16: Government Initiatives-Summary

Slide 17: National List of Essential Medicines (NLEM), Jan Aushadhi Stores (JAS)

Slide 18: Various tax reforms and control programmes

Slide 19-20: Licensing and registration of pharmaceuticals

Slide 21: Various other regulatory frameworks

Slide 22: Patent Expiry-Cardiovascular Drugs

Competitive Landscape

Slide 23: Porter's Five Forces Analysis

Slide 24: Public Trading Comparables, Top 4 Companies

Slide 25-27: Competitive Benchmarking, Key Ratios of Top 3 Companies-Operational Basis (FY 2013)

Slide 28: Competitive Benchmarking, Key Ratios of Top 3 Companies-Financial Basis (FY 2013)

Slide 29-76: Major Public Players

Slide 77-95: Major Private Players

Recent Developments

Slide 96: Recent Developments

Strategic Recommendation

Slide 97: Strategies

Appendix

Slide 98: Key Ratios Description

Slide 99: Sources of Information


List Of Figure

Macro Economic Indicators

1. GDP at Factor Cost: Quarterly (2010-11, 2011-12, 2012-13, 2013-14)

2. Inflation Rate: Monthly (Jun-Jul 2013-Oct-Nov 2013)

3. Gross Fiscal Deficit: Monthly (Feb 2013-Jul 2013)

4. Exchange Rate: Monthly (Oct 2013-March 2014)

5. Lending Rate: Annual (2008-09, 2009-10, 2010-11, 2011-12)

6. Trade Balance: Annual ( 2010-11, 2011-12, 2012-13, 2013-14)

7. FDI Annual (2009-10, 2010-11, 2011-12, 2012-13)

Market Overview

1. Global Market Size and Growth (2012-2018e)

2. Indian Market Size and Growth (2013)

3. Top Pharmaceutical segments (2010)

Drivers & Challenges

1. Deaths from CVD's

2. Number of coronary heart disease patients

Competitive Landscape

1. Competitive Benchmarking-Key Ratios of 4 Major Companies-Operational & Financial Basis (2012-2013)

2. Company profiles (All Companies)

a. Ownership Structure (All Private Companies)

b. Financial Snapshot (All Companies)

c. Key Business segments (Public Companies)

d. Key Geographic segments (Public Companies)


List Of Table

Market Overview

1. Top Selling Cardiovascular Drugs (2012)

Market Segmentation

1. Raw Materials Used For Poultry Feed

2. Raw Materials Used For Aqua Feed

Drivers & Challenges

1. Patent Expiry Date of drugs

Regulation & Patents

1. Patent Expiry-Cardiovascular Drugs

Competitive Landscape

1. Public Trading Comparables

2. Company Profiles (All Companies)

a. Company Information (All Companies)

b. Products and Services (All Companies)

c. Key People (All Companies)

d. Shareholders of the Company (All Companies)

e. Key Financial Performance Indicators (Public Companies)

f. Key Ratios (All Companies)

g. Business Highlights (All Companies)

Recent Developments

1. Recent developments

Appendix

1. Key Ratios Description

2. Sources of Information

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Public Companies

1. AstraZeneca Pharma India Ltd.

2. Sanofi India Ltd.

3. Cipla Ltd.

4. Dr. Reddy's Laboratories Ltd.

5. GlaxoSmithKline Pharmaceuticals Ltd.

6. Lupin Ltd.

7. Merck Ltd.

8. Novartis India Ltd.

9. Pfizer Ltd.

10. Ranbaxy Laboratories Ltd.

11. Sun Pharmaceutical Industries Ltd.

12. Torrent Pharmaceutical Ltd.

Private Companies

1. Bristol-Myers Squibb India Pvt. Ltd.

2. Cadila Pharmaceuticals Ltd.

3. Intas Pharmaceuticals Ltd.

4. USV Ltd.

Company Profile

Company Profile Title

Netscribes' latest market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide

Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well

READ MORE

Scope

Slide 1: Executive Summary

Macroeconomic Indicators

Slide 2: GDP at Factor Cost: Quarterly (2010-11, 2011-12, 2012-13, 2013-14), Inflation Rate: Monthly (Jun 2013-Nov 2013)

Slide 3: Gross Fiscal Deficit: Monthly (Feb 2013-Jul 2013), Exchange Rate: Half Yearly (Oct 2013-March 2014)

Slide 4: Lending Rate: Annual (2008-09, 2009-10, 2010-11, 2011-12), Trade Balance: Annual (2010-11, 2011-12, 2012-13, 2013-14), FDI: Annual (2009-10, 2010-11, 2011-12, 2012-13)

Introduction

Slide 5: Major Drug Classes

Market Overview

Slide 6-7: Global Cardiovascular Pharmaceutical Market-Overview, Indian Cardiovascular Pharmaceutical Market-Overview, Market Size & Growth (2013-2018e)

Value Chain

Slide 8-9: Market Value Chain Analysis

Drivers & Challenges

Slide 10: Drivers and Challenges-Summary

Slide 11-14: Drivers

Slide 15: Challenges

Government Initiatives

Slide 16: Government Initiatives-Summary

Slide 17: National List of Essential Medicines (NLEM), Jan Aushadhi Stores (JAS)

Slide 18: Various tax reforms and control programmes

Slide 19-20: Licensing and registration of pharmaceuticals

Slide 21: Various other regulatory frameworks

Slide 22: Patent Expiry-Cardiovascular Drugs

Competitive Landscape

Slide 23: Porter's Five Forces Analysis

Slide 24: Public Trading Comparables, Top 4 Companies

Slide 25-27: Competitive Benchmarking, Key Ratios of Top 3 Companies-Operational Basis (FY 2013)

Slide 28: Competitive Benchmarking, Key Ratios of Top 3 Companies-Financial Basis (FY 2013)

Slide 29-76: Major Public Players

Slide 77-95: Major Private Players

Recent Developments

Slide 96: Recent Developments

Strategic Recommendation

Slide 97: Strategies

Appendix

Slide 98: Key Ratios Description

Slide 99: Sources of Information


List Of Figure

Macro Economic Indicators

1. GDP at Factor Cost: Quarterly (2010-11, 2011-12, 2012-13, 2013-14)

2. Inflation Rate: Monthly (Jun-Jul 2013-Oct-Nov 2013)

3. Gross Fiscal Deficit: Monthly (Feb 2013-Jul 2013)

4. Exchange Rate: Monthly (Oct 2013-March 2014)

5. Lending Rate: Annual (2008-09, 2009-10, 2010-11, 2011-12)

6. Trade Balance: Annual ( 2010-11, 2011-12, 2012-13, 2013-14)

7. FDI Annual (2009-10, 2010-11, 2011-12, 2012-13)

Market Overview

1. Global Market Size and Growth (2012-2018e)

2. Indian Market Size and Growth (2013)

3. Top Pharmaceutical segments (2010)

Drivers & Challenges

1. Deaths from CVD's

2. Number of coronary heart disease patients

Competitive Landscape

1. Competitive Benchmarking-Key Ratios of 4 Major Companies-Operational & Financial Basis (2012-2013)

2. Company profiles (All Companies)

a. Ownership Structure (All Private Companies)

b. Financial Snapshot (All Companies)

c. Key Business segments (Public Companies)

d. Key Geographic segments (Public Companies)


List Of Table

Market Overview

1. Top Selling Cardiovascular Drugs (2012)

Market Segmentation

1. Raw Materials Used For Poultry Feed

2. Raw Materials Used For Aqua Feed

Drivers & Challenges

1. Patent Expiry Date of drugs

Regulation & Patents

1. Patent Expiry-Cardiovascular Drugs

Competitive Landscape

1. Public Trading Comparables

2. Company Profiles (All Companies)

a. Company Information (All Companies)

b. Products and Services (All Companies)

c. Key People (All Companies)

d. Shareholders of the Company (All Companies)

e. Key Financial Performance Indicators (Public Companies)

f. Key Ratios (All Companies)

g. Business Highlights (All Companies)

Recent Developments

1. Recent developments

Appendix

1. Key Ratios Description

2. Sources of Information

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Public Companies

1. AstraZeneca Pharma India Ltd.

2. Sanofi India Ltd.

3. Cipla Ltd.

4. Dr. Reddy's Laboratories Ltd.

5. GlaxoSmithKline Pharmaceuticals Ltd.

6. Lupin Ltd.

7. Merck Ltd.

8. Novartis India Ltd.

9. Pfizer Ltd.

10. Ranbaxy Laboratories Ltd.

11. Sun Pharmaceutical Industries Ltd.

12. Torrent Pharmaceutical Ltd.

Private Companies

1. Bristol-Myers Squibb India Pvt. Ltd.

2. Cadila Pharmaceuticals Ltd.

3. Intas Pharmaceuticals Ltd.

4. USV Ltd.